Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

Lyell Immunopharma, Inc. Chief Scientific Officer Gary K. Lee reported an automatic sale of 131 shares of common stock on 2026-08-10 at a weighted average price of $14.34 per share. The shares were sold to satisfy a tax withholding obligation from the settlement of vested restricted stock units, leaving 17,677 shares held directly.

Insider Trade Summary

Net Seller: 131 shares

Net Sell 1 txn

Insider Lee Gary K.

Role Chief Scientific Officer

Sold 131 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	131	$14.34	$2K

Holdings After Transaction: Common Stock — 17,677 shares (Direct)

Footnotes (2)

1. F1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
2. F2. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Key Figures

Shares sold: 131 shares Weighted average sale price: $14.34 per share Sale price range: $14.22 to $14.34 per share +1 more

4 metrics

Shares sold 131 shares Common stock automatically sold on 2026-08-10 to cover tax withholding

Weighted average sale price $14.34 per share Weighted average price for the 131 shares sold on 2026-08-10

Sale price range $14.22 to $14.34 per share Price range of individual trades within the reported sale

Shares owned after transaction 17,677 shares Directly held Lyell Immunopharma common stock after the 2026-08-10 sale

Key Terms

restricted stock units, weighted average price, tax withholding obligation

3 terms

restricted stock units financial

"tax withholding obligation from settlement of vested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported above reflects the weighted average price of the shares sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligation financial

"Shares automatically sold to cover tax withholding obligation from settlement"

FAQ

What did Lyell Immunopharma (LYEL) disclose in this Form 4 by Gary K. Lee?

Lyell Immunopharma’s Chief Scientific Officer Gary K. Lee reported an automatic sale of 131 common shares on 2026-08-10. The transaction covered tax withholding from vested restricted stock units and left him holding 17,677 shares directly.

How many Lyell Immunopharma (LYEL) shares were sold and at what price?

Gary K. Lee reported selling 131 shares of Lyell Immunopharma common stock at a weighted average price of $14.34 per share. A footnote states the individual sale prices ranged from $14.22 to $14.34 per share.

Why were Gary K. Lee’s LYEL shares sold in this Form 4 transaction?

The 131 shares were automatically sold to satisfy a tax withholding obligation arising from the settlement of vested restricted stock units. This indicates the sale was linked to equity compensation vesting rather than a discretionary open-market disposal.

How many Lyell Immunopharma (LYEL) shares does Gary K. Lee hold after the sale?

Following the reported transaction, Gary K. Lee directly holds 17,677 shares of Lyell Immunopharma common stock. This post-transaction balance is disclosed in the Form 4 and reflects his remaining direct ownership after the tax-related sale.

Was Gary K. Lee’s LYEL share sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan transaction, and no footnote notes such a plan. The sale is described instead as automatic to cover tax withholding from vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:21 PM Accepted by SEC EDGAR 08/11/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Gary K.

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S		131(1)	D	$14.34(2)	17,677	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

2. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

	/s/ Mark Meltz, Attorney-in-Fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)